Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 30 peer-reviewed journal articles Updated
Neurology · Impulse Control Disorder

Do Parkinson's Drugs Cause Impulse Control Disorders?

At a Glance

Parkinson's medications, particularly dopamine agonists, can cause impulse control disorders like compulsive gambling, shopping, or eating. These urges are a chemical reaction in the brain, not a character flaw. Consult your neurologist to safely adjust your dose; never stop abruptly.

In this answer

4 sections

01

The Link Between Dopamine Agonists and Compulsions

02

Warning Signs and Red Flags

03

Partnering with Your Loved Ones for Prevention

04

What to Do if Symptoms Occur

Yes, certain Parkinson’s medications can cause unexpected and sometimes severe behavioral changes, including gambling, shopping, or eating addictions. While it might sound like an urban legend, this is a well-documented medical side effect known as an Impulse Control Disorder (ICD). It is essential to understand that these urges are a chemical reaction to the medication, not a character flaw or a moral failing. ICDs most commonly occur in people taking a specific class of drugs called dopamine agonists (such as pramipexole and ropinirole). Understanding how these medications affect your brain’s reward system can help you and your loved ones monitor for side effects and prevent them from disrupting your life or finances.

Dopamine is a chemical in the brain that helps control movement, which is why dopamine-replacing medications are so effective for Parkinson’s disease. However, dopamine also plays a critical role in the brain’s reward and motivation pathways [1]. Dopamine agonists—medications that mimic dopamine in the brain—strongly target specific dopamine receptors (D3 receptors) located in these reward centers [2][3]. Because of this excessive stimulation, the brain can begin to place intense, irresistible value on rewarding behaviors, weakening your ability to control impulses [4][5]. This overdrive of dopamine makes dopamine agonists the primary risk factor for developing an ICD in Parkinson’s disease [6].

(Note: While dopamine agonists carry the highest risk, other Parkinson’s medications, like levodopa, can sometimes contribute to impulsive behaviors or lead to the addictive overuse of the medication itself, known as Dopamine Dysregulation Syndrome [7][8].)

Warning Signs and Red Flags

Impulse control disorders can sneak up on you, often beginning as seemingly harmless new interests before escalating into uncontrollable urges. The most common manifestations include:

  • Pathological Gambling: An uncontrollable urge to gamble, which can quickly lead to severe financial ruin [3].
  • Compulsive Shopping: Excessive buying of unneeded items, often done secretly [9].
  • Hypersexuality: An uncharacteristic and intense preoccupation with sexual thoughts, behaviors, or pornography [10].
  • Binge Eating: Consuming unusually large amounts of food in a short period, often without feeling hungry [3].
  • Punding: Closely related to impulsivity, this involves engaging in intense, repetitive, and purposeless activities, such as taking apart electronics or obsessively organizing objects for hours [11][12].

Certain factors can increase your risk for developing an ICD, including being diagnosed with Parkinson’s at a younger age, being male, having a personal or family history of addictive behaviors, or having depression [13][14][15].

Partnering with Your Loved Ones for Prevention

Because these urges are chemically driven, they can alter your judgment, and you may hide these behaviors out of a false sense of shame [16][17]. This is why it is critical to involve your family or spouse as a “second set of eyes.”

You can take proactive steps before any urges begin. Consider setting up financial guardrails, such as lowering credit card limits, setting up bank alerts for unusual spending, and giving a trusted family member access to review your accounts [18][19]. Ask your care partner to watch for “red flags” like late-night internet usage or unusual secrecy. If they notice changes, doctors can use validated screening tools, like the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease (QUIP), to quickly assess the situation [20][21].

What to Do if Symptoms Occur

If you or your loved one notice these urges developing, the primary medical strategy is adjusting your Parkinson’s medications [4][22]. This usually involves your neurologist slowly reducing or discontinuing the dopamine agonist [23][24].

Do not stop or change medications on your own. Abruptly stopping these drugs can lead to a severe condition called Dopamine Agonist Withdrawal Syndrome (DAWS), which causes intense depression, anxiety, panic attacks, and severe physical withdrawal symptoms [25][26]. Always consult your doctor to change doses.

With careful medical supervision, impulsive behaviors typically resolve once the medication dose is adjusted [27][28]. If you must stop taking a dopamine agonist, your doctor has several other effective Parkinson’s treatment options to help manage your motor symptoms safely [29][30].

Common questions in this guide

Do Parkinson's medications cause gambling or shopping addictions?
Yes, certain medications called dopamine agonists can overstimulate the brain's reward center. This can lead to impulse control disorders like pathological gambling, compulsive shopping, binge eating, or hypersexuality. These urges are a chemical reaction to the drug, not a character flaw.
Which Parkinson's drugs cause impulse control disorders?
Dopamine agonists, such as pramipexole and ropinirole, carry the highest risk for causing compulsive behaviors because they strongly target reward centers in the brain. Other medications like levodopa can also contribute, though the risk is lower.
Can I stop taking my Parkinson's medication if I develop compulsive behaviors?
No, you should never stop these medications abruptly on your own. Doing so can cause Dopamine Agonist Withdrawal Syndrome (DAWS), which leads to severe depression, anxiety, panic attacks, and physical withdrawal symptoms. Always work with your doctor to safely adjust your dose.
How can families help manage Parkinson's medication side effects?
Family members can act as a second set of eyes to watch for behavioral red flags or unusual secrecy. Before any urges begin, they can also help set up protective financial guardrails, like bank alerts, reviewing accounts, or lowering credit limits.
What is punding in Parkinson's disease?
Punding is an intense, repetitive, and purposeless activity closely related to impulsivity. People experiencing punding might spend hours taking apart electronics or obsessively organizing objects.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I currently taking a dopamine agonist, and if so, what is my specific risk for developing an impulse control disorder based on my medical history?
  2. 2.If I do develop signs of an impulse control disorder, what is our plan for safely adjusting my medications without triggering withdrawal symptoms?
  3. 3.How should my family and I monitor my behavior, and at what point should we contact you between scheduled appointments?
  4. 4.If I have to stop taking a dopamine agonist, what alternative medications or treatments can we use to keep my Parkinson's motor symptoms under control?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

What Are the Benefits of Boxing for Parkinson's Disease?Do All Parkinson's Patients Need a Wheelchair?Does Deep Brain Stimulation Slow Parkinson's Progression?Does Parkinson's Disease Affect Life Expectancy?Can I Get Focused Ultrasound Instead of DBS for Parkinson's?How Is Parkinson's Diagnosed vs. Essential Tremor?How Long Is the Parkinson's Disease Honeymoon Period?How to Take Levodopa with Protein Meals for Parkinson'sParkinson's Speech Therapy: Does It Help Hypophonia?Is Loss of Smell an Early Sign of Parkinson's Disease?Is Parkinson's Disease Genetic or Hereditary?Do I Need a Movement Disorder Specialist for Parkinson's?Parkinson's Tremor vs Dyskinesia: What's the Difference?How Can You Sleep Safely with REM Sleep Behavior Disorder?What Causes Dizziness in Parkinson's Disease?Why Does Parkinson's Medication Wear Off?Tremor Dominant Parkinson's: How Fast Does It Progress?

References

References (30)
  1. 1

    Neural correlates of impulse control behaviors in Parkinson's disease: Analysis of multimodal imaging data.

    Baagil H, Hohenfeld C, Habel U, et al.

    NeuroImage. Clinical 2023; (37()):103315 doi:10.1016/j.nicl.2023.103315.

    PMID: 36610308
  2. 2

    Impulse Control Disorders in Parkinson's Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological Management.

    Carbone F, Djamshidian A

    CNS drugs 2024; (38(6)):443-457 doi:10.1007/s40263-024-01087-y.

    PMID: 38613665
  3. 3

    [Predictors and modifiers of impulse control disorders in Parkinson`s disease].

    Sapronova MR, Shnayder NA

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2016; (116(11)):145-156 doi:10.17116/jnevro2016116111145-156.

    PMID: 28635753
  4. 4

    Screening for impulse control disorders in Parkinson's disease and dopamine agonist use: a study of pharmacokinetic and psychological risk factors.

    Contin M, Lopane G, Marini L, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2023; (44(2)):565-572 doi:10.1007/s10072-022-06485-y.

    PMID: 36350455
  5. 5

    Dopamine drives binge-like consumption of a palatable food in experimental Parkinsonism.

    Mineo D, Cacace F, Mancini M, et al.

    Movement disorders : official journal of the Movement Disorder Society 2019; (34(6)):821-831 doi:10.1002/mds.27683.

    PMID: 31002748
  6. 6

    Does the Country Make a Difference in Impulse Control Disorders? A Systematic Review.

    Parra-Díaz P, Chico-García JL, Beltrán-Corbellini Á, et al.

    Movement disorders clinical practice 2021; (8(1)):25-32 doi:10.1002/mdc3.13128.

    PMID: 33426155
  7. 7

    Risk factors and outcome of dopamine dysregulation syndrome in a large Chinese Parkinson's disease cohort.

    Xiao Y, Kang S, Ou R, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026; (47(1)):156.

    PMID: 41528495
  8. 8

    Advanced Therapies for the Management of Dopamine Dysregulation Syndrome in Parkinson's Disease.

    Sasikumar S, Matta R, Munhoz RP, et al.

    Movement disorders clinical practice 2021; (8(3)):400-405 doi:10.1002/mdc3.13154.

    PMID: 33816669
  9. 9

    Analysis of Impulse Control Disorders (ICDs) and Factors Associated with Their Development in a Parkinson's Disease Population.

    García-Rubio MI, Otero-Cerdeira ME, Toledo-Lozano CG, et al.

    Healthcare (Basel, Switzerland) 2021; (9(10)) doi:10.3390/healthcare9101263.

    PMID: 34682943
  10. 10

    Reckless Generosity, Parkinson's Disease and Dopamine: A Case Series and Literature Review.

    Amstutz D, Michelis JP, Debove I, et al.

    Movement disorders clinical practice 2021; (8(3)):469-473 doi:10.1002/mdc3.13156.

    PMID: 33816681
  11. 11

    Impulse-Control Disorders in Parkinson's Disease: A Meta-Analysis and Review of Case-Control Studies.

    Molde H, Moussavi Y, Kopperud ST, et al.

    Frontiers in neurology 2018; (9()):330 doi:10.3389/fneur.2018.00330.

    PMID: 29872418
  12. 12

    Parkinson's Impulse-Control Scale for the Severity Rating of Impulse-Control Behaviors in Parkinson's Disease: A Semistructured Clinical Assessment Tool.

    Okai D, Askey-Jones S, Mack J, et al.

    Movement disorders clinical practice 2016; (3(5)):494-499 doi:10.1002/mdc3.12316.

    PMID: 27774496
  13. 13

    Impulse control disorders in Parkinson disease and RBD: A longitudinal study of severity.

    Baig F, Kelly MJ, Lawton MA, et al.

    Neurology 2019; (93(7)):e675-e687 doi:10.1212/WNL.0000000000007942.

    PMID: 31311842
  14. 14

    Impulse control disorders in Parkinson's disease patients with RLS: a cross sectional-study.

    Marques A, Figorilli M, Pereira B, et al.

    Sleep medicine 2018; (48()):148-154 doi:10.1016/j.sleep.2018.02.004.

    PMID: 29913341
  15. 15

    Impulsivity Traits in Parkinson's Disease: A Systematic Review and Meta-Analysis.

    Giovannelli F, Gavazzi G, Noferini C, et al.

    Movement disorders clinical practice 2023; (10(10)):1448-1458 doi:10.1002/mdc3.13839.

    PMID: 37868926
  16. 16

    Gender Differences in Impulse Control Disorders and Related Behaviors in Patients with Parkinson's Disease and its Impact on Quality of Life.

    Paul BS, Singh G, Bansal N, et al.

    Annals of Indian Academy of Neurology 2020; (23(5)):632-637 doi:10.4103/aian.AIAN_47_20.

    PMID: 33623263
  17. 17

    The relationship between Parkinson's disease and sexual hyperactivity secondary to drug treatment: A systematic review.

    Aparicio-López V, Rueda-Extremera M, Cantero-García M

    Journal of psychopharmacology (Oxford, England) 2025; (39(4)):316-327 doi:10.1177/02698811241277200.

    PMID: 39282911
  18. 18

    Screening for Problematic Internet Use May Help Identify Impulse Control Disorders in Parkinson's Disease.

    Kovács M, Makkos A, Pintér D, et al.

    Behavioural neurology 2019; (2019()):4925015 doi:10.1155/2019/4925015.

    PMID: 30863462
  19. 19

    Impulse control disorders in pituitary adenoma: What do we know and what we still don't know in almost two decades?

    Kadioglu P, Glezer A

    Pituitary 2025; (28(3)):71 doi:10.1007/s11102-025-01533-0.

    PMID: 40456893
  20. 20

    Impulse control disorders in Parkinson's disease: A systematic review on the psychometric properties of the existing measures.

    Izzo VA, Donati MA, Ramat S, Primi C

    PloS one 2019; (14(6)):e0217700 doi:10.1371/journal.pone.0217700.

    PMID: 31163065
  21. 21

    Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre.

    Hamblin R, White M, Fountas A, Karavitaki N

    Pituitary 2025; (28(3)):52 doi:10.1007/s11102-025-01517-0.

    PMID: 40257641
  22. 22

    Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study.

    Fusaroli M, Giunchi V, Battini V, et al.

    Psychiatry and clinical neurosciences 2023; (77(3)):160-167 doi:10.1111/pcn.13511.

    PMID: 36436204
  23. 23

    Impulse-Control Disorders and Restless Legs Syndrome in Parkinson's Disease: Are they Close Together or Far Apart?

    Desai I, Kumar N

    Annals of Indian Academy of Neurology 2023; (26(3)):217-218 doi:10.4103/aian.aian_166_23.

    PMID: 37538429
  24. 24

    Amantadine Revisited: A Contender for Initial Treatment in Parkinson's Disease?

    Marmol S, Feldman M, Singer C, Margolesky J

    CNS drugs 2021; (35(11)):1141-1152 doi:10.1007/s40263-021-00862-5.

    PMID: 34648150
  25. 25

    Dopamine agonist withdrawal syndrome associated factors: A retrospective chart review.

    Garcia X, Mohammad ME, Patel S, et al.

    Clinical parkinsonism & related disorders 2022; (7()):100153 doi:10.1016/j.prdoa.2022.100153.

    PMID: 35909701
  26. 26

    Suicide attempt in a dopamine agonist withdrawal syndrome in Parkinson's disease.

    Espindola M, Rojas NG, Vaisentein G, et al.

    Parkinsonism & related disorders 2024; (121()):106017 doi:10.1016/j.parkreldis.2024.106017.

    PMID: 38401377
  27. 27

    Gambling Disorder in Parkinson's Disease: A Scoping Review on the Challenge of Rehabilitation Strategies.

    Culicetto L, Impellizzeri F, Lo Buono V, et al.

    Journal of clinical medicine 2025; (14(3)) doi:10.3390/jcm14030737.

    PMID: 39941408
  28. 28

    Longitudinal analysis of impulse control disorders in Parkinson disease.

    Corvol JC, Artaud F, Cormier-Dequaire F, et al.

    Neurology 2018; (91(3)):e189-e201 doi:10.1212/WNL.0000000000005816.

    PMID: 29925549
  29. 29

    Developments in impulse control behaviours of Parkinson's disease.

    Zurowski M, O'Brien JD

    Current opinion in neurology 2015; (28(4)):387-92 doi:10.1097/WCO.0000000000000209.

    PMID: 26110803
  30. 30

    Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease.

    Lizarraga KJ, Fox SH, Strafella AP, Lang AE

    Clinics in geriatric medicine 2020; (36(1)):105-118 doi:10.1016/j.cger.2019.09.004.

    PMID: 31733691

This information about Parkinson's medication side effects is for educational purposes only. Never stop or change your Parkinson's medications without consulting your neurologist, as abrupt changes can cause severe withdrawal symptoms.

Get notified when new evidence is published on Parkinson's Disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.